OncoMatch/Clinical Trials/NCT06235125
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Is NCT06235125 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Cytalux for osteosarcoma.
Treatment: Cytalux — Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Osteosarcoma
Sarcoma
Disease stage
Metastatic disease required
Demographics
Lab requirements
Kidney function
Impaired renal function defined as eGFR< 50 mL/min/1.73m2 [excluded]
Liver function
Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >2x ULN for total bilirubin except in subjects with Gilbert's syndrome [excluded]
Impaired renal function defined as eGFR< 50 mL/min/1.73m2; Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >2x ULN for total bilirubin except in subjects with Gilbert's syndrome
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ann & Robert H. Lurie Children's Hospital · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06235125 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 6 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages